Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank54
3Y CAGR+20.6%
5Y CAGR-9.2%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+20.6%/yr
vs +30.8%/yr prior
5Y CAGR
-9.2%/yr
Recent acceleration
Acceleration
-10.2pp
Decelerating
Percentile
P54
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $39.46M | -37.5% |
| 2024 | $63.18M | -14.8% |
| 2023 | $74.15M | +229.6% |
| 2022 | $22.50M | -72.4% |
| 2021 | $81.49M | +27.4% |
| 2020 | $63.96M | -56.0% |
| 2019 | $145.34M | +1791.2% |
| 2018 | $7.68M | +1145.5% |
| 2017 | $617000.00 | -99.5% |
| 2016 | $115.78M | - |